Neurology & GI CEDD, GlaxoSmithKline, Third Avenue, Harlow, Essex, CM19 5AW, UK.
Purinergic Signal. 2007 Mar;3(1-2):163-9. doi: 10.1007/s11302-006-9031-1. Epub 2007 Jan 3.
The P2X ₇purinoceptor is unique amongst the P2X receptor family in that its activation is able to stimulate the release of mature, biologically active interleukin-1beta (IL-1β), as well as a variety of other proinflammatory cytokines. Coupled with the predominate localisation of this receptor to immunocytes of haemopoetic origin, this receptor is an obvious candidate to play a major and pivotal role in processes of pain and inflammation. Using genetically modified animals that lack the P2X₇ receptor, several investigators have shown that these mice do indeed demonstrate a blunted inflammatory response, and fail to develop pain following both inflammatory and neuropathic insult. These animals also show altered cytokine production in response to inflammatory stimulus, which is far broader than merely modulation of IL-1β release. In this short article, we review the role of the P2X₇ receptor in modulating the release of cytokines and other mediators, and discuss the findings made from P2X₇ receptor-deficient animals. As well as highlighting outstanding questions regarding this intriguing receptor, we also speculate as to the potential therapeutic benefit of P2X₇ receptor modulation.
P2X7 嘌呤能受体在 P2X 受体家族中是独一无二的,因为它的激活能够刺激成熟的、具有生物活性的白细胞介素-1β(IL-1β)以及多种其他促炎细胞因子的释放。 加上这种受体主要定位于造血来源的免疫细胞,该受体显然是在疼痛和炎症过程中发挥主要和关键作用的候选者。 使用缺乏 P2X7 受体的基因修饰动物,一些研究人员表明,这些小鼠确实表现出炎症反应减弱,并且在炎症和神经病理性损伤后均不会产生疼痛。 这些动物对炎症刺激的细胞因子产生也发生了改变,其范围远远超出了仅仅调节 IL-1β 的释放。 在这篇短文中,我们回顾了 P2X7 受体在调节细胞因子和其他介质释放中的作用,并讨论了缺乏 P2X7 受体的动物的发现。 除了突出这个有趣的受体的悬而未决的问题外,我们还推测 P2X7 受体调节的潜在治疗益处。